Mankind Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Mankind Pharma Limited (NSE:MANKIND) recently reported its quarterly numbers. It looks like a credible result overall - although revenues of ₹40b were in line with what the analysts predicted, Mankind Pharma surprised by delivering a statutory profit of ₹13.74 per share, a notable 10% above expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Mankind Pharma after the latest results.
Taking into account the latest results, the current consensus from Mankind Pharma's 19 analysts is for revenues of ₹160.2b in 2027. This would reflect a solid 8.7% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to ascend 15% to ₹56.90. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹159.9b and earnings per share (EPS) of ₹57.12 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Mankind Pharma
There were no changes to revenue or earnings estimates or the price target of ₹2,718, suggesting that the company has met expectations in its recent result. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Mankind Pharma, with the most bullish analyst valuing it at ₹3,220 and the most bearish at ₹2,057 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Mankind Pharma shareholders.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Mankind Pharma's revenue growth is expected to slow, with the forecast 12% annualised growth rate until the end of 2027 being well below the historical 17% p.a. growth over the last three years. Compare this to the 181 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 12% per year. So it's pretty clear that, while Mankind Pharma's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at ₹2,718, with the latest estimates not enough to have an impact on their price targets.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Mankind Pharma going out to 2029, and you can see them free on our platform here.
You can also view our analysis of Mankind Pharma's balance sheet, and whether we think Mankind Pharma is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.